Physician profile

Paul Nager

Cardiovascular Disease · Overland Park, KS

NPI 1821047440

$10,004.08

in general payments reported to CMS, 2019-2025

41 companies · $1,009 in 2025

The $1,009 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,521.18

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abiomed $2,382.26 2019-2022
Amgen INC. $1,125.26 2019-2025 Repatha, Repatha
Boston Scientific Corporation $1,021.33 2019-2025 Watchman Flx, Emblem Mri S-Icd, Watchman Access System
E.R. Squibb & Sons, L.L.C. $500.57 2019-2025 Eliquis, Camzyos
Novartis Pharmaceuticals Corporation $500.46 2019-2025
Astellas Pharma US INC $440.10 2019-2020
Janssen Pharmaceuticals, INC $436.94 2019-2024 Xarelto
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $427.81 2019-2025 Lifevest
Medtronic, INC. $311.11 2021-2025 Linq II, Affera Mapping System, Micra
Irhythm Technologies, INC. $304.38 2023-2024 Zio Xt Patch, Zio Monitor
Shockwave Medical, INC $285.03 2022-2023 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Pfizer INC. $232.19 2019-2024
Merck Sharp & Dohme LLC $202.78 2021-2025 Verquvo
Sanofi-Aventis U.S. LLC $186.40 2019-2023
Livanova USA, INC. $152.02 2019
Show all 41 companies
CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $149.72 2021-2025 Ozempic, Rybelsus, Wegovy
Biotronik INC. $136.98 2025 Biomonitor, Amvia Edge
Astrazeneca Pharmaceuticals Lp $133.30 2019-2024 Wainua
Amarin Pharma, INC. $113.50 2019-2021
Boehringer Ingelheim Pharmaceuticals, INC. $112.06 2020-2025 Jardiance
Abbott Laboratories $110.77 2019-2023 Cardiomems
Actelion Pharmaceuticals US, INC. $84.97 2021
Philips North America LLC $79.54 2022-2025 Ecc Solutions
Medtronic Vascular, INC. $62.24 2019-2020
Kestra Medical Technology Services, INC. $58.25 2025 Assure Wcd
Lexicon Pharmaceuticals, INC. $45.80 2024
Lemaitre Vascular, INC. $42.83 2022
Vital Connect, INC $42.20 2025 Vitalpatch Rtm
Z-Medica, LLC $40.08 2019
Alnylam Pharmaceuticals INC. $33.62 2025 Amvuttra
Scpharmaceuticals INC. $32.76 2023
Lundbeck LLC $31.67 2019-2020
Regeneron Healthcare Solutions, INC. $30.95 2024 Evkeeza
Amryt Pharma Holdings Ltd $30.34 2020-2021
C. R. Bard, INC. & Subsidiaries $24.90 2019
Genzyme Corporation $20.06 2024
Heartflow, INC. $19.68 2025
Penumbra, INC. $17.41 2024 Indigo System
Kiniksa Pharmaceuticals International, Plc $14.82 2024 Arcalyst
Bayer Healthcare Pharmaceuticals INC. $13.99 2025
Esperion Therapeutics, INC. $13.00 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Paul Nager

$10,004.08

in general payments reported 2019-2025

Years
2019-2025
Top company
Abiomed
Context
The $1,009 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/36914/paul-nager

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.